BioCentury | Jan 9, 2021
Translation in Brief

Fusing camelid antibodies to toxin derivatives to treat botulism; plus BioNTech applies platform to multiple sclerosis, a molecule that stops axon degeneration and more

...derivatives shortened the duration of muscle paralysis and increased survival in mice. Wake Forest and New York University Langone Medical Center...
BioCentury | Jan 8, 2021
Product Development

Caplan sees a host of bioethical turning points coming out of the pandemic

...it doesn't snap back that fast. C. Simone Fishburn NYU Langone Medical Center COVID19...
BioCentury | Nov 30, 2020
Management Tracks

New CMO and Takeda alum Palmer adds to Ascletis’ push into NASH

...of NASH and other liver disease programs. She has also served as clinical professor at NYU Langone Medical Center...
BioCentury | Oct 21, 2020
Regulation

Ethics arising from EUAs could disrupt COVID-19 vaccine trials

...Abraham, a pathology professor at SUNY Upstate Medical University and Arthur Caplan, a bioethicist at NYU Langone Medical Center...
...designs, etc.).” Steve Usdin Pfizer Inc. BioNTech SE U.S. Food and Drug Administration (FDA) Johnson & Johnson Janssen Pharmaceuticals ​ Biotechnology Innovation Organization NYU Langone Medical Center COVID-19 cov19pol cov19count ethics Infectious...
BioCentury | Oct 6, 2020
Politics, Policy & Law

Trump treatment resurfaces compassionate use quandaries

...implementing allocation policies. Steve Usdin Regeneron Pharmaceuticals Inc. Johnson & Johnson NYU Langone Medical Center COVID-19 cov19pol cov19count convalescent...
BioCentury | Mar 28, 2020
Translation in Brief

17 FDA-approved drugs show activity against SARS-CoV-2; two groups seek COVID-19 patient-derived mAbs; plus NYU, Scholar Rock and LIfT-King's College

...Angiotensin-converting enzyme 2 IL-10 - Interleukin-10 TGFβ1 - Transforming growth factor β 1 BioCentury Staff Berkeley Lights Inc. New York University Langone Medical Center University...
BioCentury | Feb 1, 2020
Distillery Therapeutics

CDK7 inhibition for treating small cell lung cancer

...H. et al. Cancer Cell ; published online Dec. 26, 2019 doi:10.1016/j.ccell.2019.11.003 CONTACT: Hua Zhang, New York University Langone Medical Center...
...Nathanael S. Gray, Dana-Farber Cancer Institute, Boston, Mass.; Harvard Medical School, Boston, Mass. email: nathanael_gray@dfci.harvard.edu Claire Quang New York University Langone Medical Center Dana-Farber...
BioCentury | Jun 24, 2019
Tools & Techniques

A new flavor of allosteric modulators: synthetic proteins

...screening platform described in the PNAS study. The collaborators are open to partnerships. Allison Johnson, Staff Writer New York University Langone Medical Center Relay...
BioCentury | Jun 8, 2019
Product Development

ASCO 2019 sessions provide guidance on expanding patient pools for clinical trials

...Inteliquet Biopharma, Memphis, Tenn. IQVIA Holdings Inc. (NYSE:IQV), Durham, N.C. Levine Cancer Institute, Charlotte, N.C. New York University Langone Medical Center...
BioCentury | May 10, 2019
Targets & Mechanisms

The tumor microbiome emerges as a new source of translational opportunities

...Cancer Research UK, London, U.K. Dana-Farber Cancer Institute, Boston, Mass. Merck KGaA (Xetra:MRK), Darmstadt, Germany New York University Langone Medical Center...
...TIGIT - T cell immunoreceptor with Ig and ITIM domains Karen Tkach Tuzman, Associate Editor BiomX Ltd. Merck KGaA NYU Langone Medical Center University...
Items per page:
1 - 10 of 47
BioCentury | Jan 9, 2021
Translation in Brief

Fusing camelid antibodies to toxin derivatives to treat botulism; plus BioNTech applies platform to multiple sclerosis, a molecule that stops axon degeneration and more

...derivatives shortened the duration of muscle paralysis and increased survival in mice. Wake Forest and New York University Langone Medical Center...
BioCentury | Jan 8, 2021
Product Development

Caplan sees a host of bioethical turning points coming out of the pandemic

...it doesn't snap back that fast. C. Simone Fishburn NYU Langone Medical Center COVID19...
BioCentury | Nov 30, 2020
Management Tracks

New CMO and Takeda alum Palmer adds to Ascletis’ push into NASH

...of NASH and other liver disease programs. She has also served as clinical professor at NYU Langone Medical Center...
BioCentury | Oct 21, 2020
Regulation

Ethics arising from EUAs could disrupt COVID-19 vaccine trials

...Abraham, a pathology professor at SUNY Upstate Medical University and Arthur Caplan, a bioethicist at NYU Langone Medical Center...
...designs, etc.).” Steve Usdin Pfizer Inc. BioNTech SE U.S. Food and Drug Administration (FDA) Johnson & Johnson Janssen Pharmaceuticals ​ Biotechnology Innovation Organization NYU Langone Medical Center COVID-19 cov19pol cov19count ethics Infectious...
BioCentury | Oct 6, 2020
Politics, Policy & Law

Trump treatment resurfaces compassionate use quandaries

...implementing allocation policies. Steve Usdin Regeneron Pharmaceuticals Inc. Johnson & Johnson NYU Langone Medical Center COVID-19 cov19pol cov19count convalescent...
BioCentury | Mar 28, 2020
Translation in Brief

17 FDA-approved drugs show activity against SARS-CoV-2; two groups seek COVID-19 patient-derived mAbs; plus NYU, Scholar Rock and LIfT-King's College

...Angiotensin-converting enzyme 2 IL-10 - Interleukin-10 TGFβ1 - Transforming growth factor β 1 BioCentury Staff Berkeley Lights Inc. New York University Langone Medical Center University...
BioCentury | Feb 1, 2020
Distillery Therapeutics

CDK7 inhibition for treating small cell lung cancer

...H. et al. Cancer Cell ; published online Dec. 26, 2019 doi:10.1016/j.ccell.2019.11.003 CONTACT: Hua Zhang, New York University Langone Medical Center...
...Nathanael S. Gray, Dana-Farber Cancer Institute, Boston, Mass.; Harvard Medical School, Boston, Mass. email: nathanael_gray@dfci.harvard.edu Claire Quang New York University Langone Medical Center Dana-Farber...
BioCentury | Jun 24, 2019
Tools & Techniques

A new flavor of allosteric modulators: synthetic proteins

...screening platform described in the PNAS study. The collaborators are open to partnerships. Allison Johnson, Staff Writer New York University Langone Medical Center Relay...
BioCentury | Jun 8, 2019
Product Development

ASCO 2019 sessions provide guidance on expanding patient pools for clinical trials

...Inteliquet Biopharma, Memphis, Tenn. IQVIA Holdings Inc. (NYSE:IQV), Durham, N.C. Levine Cancer Institute, Charlotte, N.C. New York University Langone Medical Center...
BioCentury | May 10, 2019
Targets & Mechanisms

The tumor microbiome emerges as a new source of translational opportunities

...Cancer Research UK, London, U.K. Dana-Farber Cancer Institute, Boston, Mass. Merck KGaA (Xetra:MRK), Darmstadt, Germany New York University Langone Medical Center...
...TIGIT - T cell immunoreceptor with Ig and ITIM domains Karen Tkach Tuzman, Associate Editor BiomX Ltd. Merck KGaA NYU Langone Medical Center University...
Items per page:
1 - 10 of 47